Medical management
As noted earlier, many aortopathies are not known until pregnancy, and medical management, α-Methyldopa or beta blocker can be utilised to slow aortic growth and advised by the ESC38. Gersonyet al . contested this, having found no difference between beta blocker use in a meta-analysis, and no change in dilatation39. In addition, beta blockade has been shown in several studies to have side effects, such as intrauterine growth restriction and fetal bradycardia15. A study of Celiprolol, however, had a decrease of arterial events (20%) in a randomised control trial compared to control (50%), but this has not been demonstrated in patients with aortic disease15.